News & Events

Strategic activation unites best-in-class technology with end-to-end development solutions to optimize therapeutic development process CORALVILLE, Iowa and WALTHAM, Mass. (July 15, 2024)) –Integrated DNA Technologies (IDT), a global leader in CRISPR genome editing solutions, inked a licensing agreement with SeQure Dx, a company focused on off-target analysis for preclinical and clinical gene modification customers, bolstering […]

The world of gene editing is one where the impossible becomes possible, and the future of healthcare is being rewritten before our eyes. CRISPR and other gene editing based therapeutics represent a transformative step in healthcare, moving us from an age of treatment and living with disease, to one of cure. In the last year […]

As the calendar flips to 2024, we at SeQure Dx find ourselves at an exhilarating crossroads. With a year of groundbreaking achievements behind us and the horizon filled with promising opportunities, we’re eager to share our journey and the future we’re passionately working towards.

Synthego, a leading provider of genome engineering solutions, and SeQure Dx, a company focused on off-target analysis for preclinical and clinical gene modification customers, have announced a strategic partnership to provide CRISPR-based therapeutics developers with comprehensive off-target editing analytical services that include best-in-class technology and turn-key end-to-end development solutions.

KromaTiD and SeQure Dx announced today a partnership to market a comprehensive and integrated analysis of off-target gene editing in support of cell and gene therapy research, Investigational New Drug (IND) applications and drug product development.

SeQure Dx, Inc, a leading genomics intelligence company, announced today it will present new data at the 2023 American Society of Gene and Cell Therapy Annual Meeting from May 16 – 20 in Los Angeles.

Building on Dr. J. Keith Joung’s ONE-seq platform, SeQure Dx has developed a portfolio of assays and data solutions to find, assess, and manage off-target risks from discovery to clinical development to patient impact.

Patented technology addresses emerging need for personalized diagnostics that assess the risks of gene-editing therapies